Neoadjuvant chemoradiotherapy with radiation dose escalation with contact x-ray brachytherapy boost or external beam radiotherapy boost for organ preservation in early cT2–cT3 rectal adenocarcinoma (OPERA): a phase 3, randomised controlled trial

医学 近距离放射治疗 外照射放疗 直肠 放射治疗 放化疗 卡培他滨 结直肠癌 放射科 外科 核医学 癌症 内科学
作者
Jean‐Pierre Gérard,N. Barbet,Renaud Schiappa,Nicolas Magné,I. Martel,Laurent Mineur,M. Deberne,Thomas Zilli,A.S. Dhadda,Arthur Sun Myint
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:8 (4): 356-367 被引量:118
标识
DOI:10.1016/s2468-1253(22)00392-2
摘要

Organ preservation after reaching clinical complete response on neoadjuvant therapy is gaining interest for rectal cancers, although the role of radiation dose escalation is still not known. We aimed to determine whether a contact x-ray brachytherapy boost, following or preceding neoadjuvant chemoradiotherapy, increases the probability of 3-year organ preservation for patients with early rectal cancers.OPERA was a multicentre, open-label, phase 3 randomised controlled trial done at 17 cancer centres that included operable patients, aged 18 years or older, with cT2, cT3a, or cT3b adenocarcinoma of low-mid rectum, tumours of less than 5 cm in diameter, and cN0 or cN1 smaller than 8 mm. All patients received neoadjuvant chemoradiotherapy and 45 Gy external beam radiotherapy in 25 fractions over 5 weeks with concurrent oral capecitabine (825 mg/m2 twice a day). Patients were randomly assigned (1:1) to receive a boost of external beam radiotherapy at 9 Gy in five fractions (group A) or a boost with contact x-ray brachytherapy (90 Gy in three fractions; group B). Randomisation was done centrally using an independent web-based system and stratified by trial centre, tumour classification (cT2 vs cT3a or cT3b), tumour distance from rectum (<6 cm from anal verge vs ≥6 cm), and tumour diameter (<3 cm vs ≥3 cm). Treatment in group B was stratified by tumour diameter, with the contact x-ray brachytherapy boost given before neoadjuvant chemoradiotherapy in patients with tumours smaller than 3 cm. The primary outcome was organ preservation at 3 years, analysed in the modified intention-to-treat population. This study was registered with ClinicalTrials.gov, NCT02505750, and is ongoing.Between June 14, 2015, and June 26, 2020, 148 patients were assessed for eligibility and were randomly assigned to group A (n=74) or group B (n=74). Seven patients withdrew their consent (five in group A and two in group B). 141 patients were included in the primary efficacy analysis, including 69 assigned to group A (29 with tumours <3 cm in diameter and 40 with tumours ≥3 cm) and 72 assigned to group B (32 with tumours <3 cm and 40 with tumours ≥3 cm). After a median follow-up of 38·2 months (IQR 34·2-42·5), the 3-year organ preservation rate was 59% (95% CI 48-72) in group A versus 81% (72-91) in group B (hazard ratio [HR] 0·36, 95% CI 0·19-0·70; p=0·0026). For patients with tumours less than 3 cm in diameter, 3-year organ preservation rates were 63% (95% CI 47-84) in group A versus 97% (91-100) in group B (HR 0·07, 95% CI 0·01-0·57; p=0·012). For patients with tumours of 3 cm or larger, 3-year organ preservation rates were 55% (95% CI 41-74) in group A versus 68% (54-85) in group B (HR 0·54, 95% CI 0·26-1·10; p=0·11). 21 (30%) patients in group A and 30 (42%) in group B had an early grade 2-3 adverse event (p=1·0). The most common early grade 2-3 adverse events were proctitis (four [6%] in group A, nine [13%] in group B) and radiation dermatitis (seven [10%] in group A, two [3%] in group B). The main late side-effect was grade 1-2 rectal bleeding due to telangiectasia, which was more frequent in group B (37 [63%] of 59) than in group A (five [12%] of 43; p<0·0001) and subsided after 3 years.Neoadjuvant chemoradiotherapy with a contact x-ray brachytherapy boost significantly improved the 3-year organ preservation rate, particularly for patients with tumours smaller than 3 cm who were treated with contact x-ray brachytherapy first, compared with neoadjuvant chemoradiotherapy with a boost via external beam radiotherapy. This approach could be discussed and offered to operable patients with early cT2-cT3 disease who are keen to avoid surgery and seek organ preservation.The French Programme Hospitalier de Recherche Cinique.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
星辰大海应助拓小八采纳,获得10
2秒前
Tao发布了新的文献求助10
3秒前
3秒前
Tangviva1988发布了新的文献求助10
3秒前
阳光沛柔发布了新的文献求助10
4秒前
SYLH应助cyn0762采纳,获得30
5秒前
9秒前
打打应助Tine采纳,获得30
10秒前
研友_VZG7GZ应助EED采纳,获得10
11秒前
缥缈问柳应助wjw采纳,获得10
11秒前
DijiaXu应助朝朝采纳,获得10
13秒前
sanyecai完成签到,获得积分10
13秒前
李健的小迷弟应助高铭泽采纳,获得10
16秒前
Zsl121完成签到,获得积分10
17秒前
17秒前
爆米花应助肖肖采纳,获得10
18秒前
18秒前
冬至完成签到,获得积分10
19秒前
20秒前
shenzhou9完成签到,获得积分10
20秒前
量子星尘发布了新的文献求助10
20秒前
21秒前
lll完成签到,获得积分20
23秒前
欣喜豌豆完成签到,获得积分10
25秒前
彭于晏应助雨过天晴采纳,获得10
25秒前
李健的小迷弟应助唐_采纳,获得10
26秒前
云辞忧发布了新的文献求助10
26秒前
华仔应助Livrik采纳,获得10
26秒前
EED发布了新的文献求助10
27秒前
28秒前
29秒前
30秒前
赘婿应助hhhi采纳,获得10
30秒前
领导范儿应助康康采纳,获得10
31秒前
李健的小迷弟应助blue采纳,获得10
31秒前
33秒前
33秒前
可爱的函函应助智慧爷爷采纳,获得10
33秒前
研友_VZG7GZ应助dsdsd采纳,获得10
33秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
‘Unruly’ Children: Historical Fieldnotes and Learning Morality in a Taiwan Village (New Departures in Anthropology) 400
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
基于可调谐半导体激光吸收光谱技术泄漏气体检测系统的研究 350
Robot-supported joining of reinforcement textiles with one-sided sewing heads 320
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3988868
求助须知:如何正确求助?哪些是违规求助? 3531255
关于积分的说明 11253071
捐赠科研通 3269858
什么是DOI,文献DOI怎么找? 1804822
邀请新用户注册赠送积分活动 881994
科研通“疑难数据库(出版商)”最低求助积分说明 809035